Crucell N.V. And DSM Pharmaceuticals, Inc. Intensify Collaboration And Development Of PER.C6(R) Human Cell Line

Sittard/Leiden, The Netherlands, February 8, 2007 - DSM Biologics, a business unit of DSM Pharmaceuticals, and Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) announced today that they have further intensified their PER.C6® collaboration, by executing an agreement to expand the existing commercial relationship to include new classes of proteins, including biosimilar protein products. As part of the agreement, DSM paid Crucell an undisclosed amount in exchange for additional license rights and a higher share of future licensing income.

MORE ON THIS TOPIC